Please use this identifier to cite or link to this item:
Title: Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease.
Austin Authors: Fowler, Christopher;Rainey-Smith, Stephanie R;Bird, Sabine;Bomke, Julia;Bourgeat, Pierrick;Brown, Belinda M;Burnham, Samantha C;Bush, Ashley I;Chadunow, Carolyn;Collins, Steven;Doecke, James;Doré, Vincent ;Ellis, Kathryn A;Evered, Lis;Fazlollahi, Amir;Fripp, Jurgen;Gardener, Samantha L;Gibson, Simon;Grenfell, Robert;Harrison, Elise;Head, Richard;Jin, Liang;Kamer, Adrian;Lamb, Fiona ;Lautenschlager, Nicola T;Laws, Simon M;Li, Qiao-Xin;Lim, Lucy ;Lim, Yen Ying;Louey, Andrea;Macaulay, S Lance;Mackintosh, Lucy;Martins, Ralph N;Maruff, Paul;Masters, Colin L ;McBride, Simon;Milicic, Lidija;Peretti, Madeline;Pertile, Kelly;Porter, Tenielle;Radler, Morgan;Rembach, Alan;Robertson, Joanne;Rodrigues, Mark;Rowe, Christopher C ;Rumble, Rebecca;Salvado, Olivier;Savage, Greg;Silbert, Brendan;Soh, Magdalene;Sohrabi, Hamid R;Taddei, Kevin;Taddei, Tania;Thai, Christine;Trounson, Brett;Tyrrell, Regan ;Vacher, Michael;Varghese, Shiji;Villemagne, Victor L ;Weinborn, Michael;Woodward, Michael M ;Xia, Ying;Ames, David
Affiliation: Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
CSIRO Data61, Brisbane, QLD, Australia
Department of Psychology, Macquarie University, Sydney, NSW, Australia
Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
Cooperative Research Council for Mental Health, Melbourne, VIC, Australia
Geriatric Medicine
Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA, Australia
School of Psychological Science, University of Western Australia, Crawley, WA, Australia
Molecular Imaging and Therapy
The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
University of Melbourne Academic Unit for Psychiatry of Old Age, Parkville, VIC, Australia
Melbourne School of Psychological Sciences, Melbourne, VIC, Australia
Collaborative Genomics and Translation Group, Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia
Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, VIC, Australia
Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
National Ageing Research Institute (NARI), Parkville, VIC, Australia
Department of Anaesthesia and Acute Pain Medicine, St Vincent's Hospital Melbourne, Victoria Parade, Fitzroy, VIC, Australia
Cogstate Limited, Melbourne, VIC, Australia
Issue Date: 3-Jun-2021
Date: 2021
Publication information: Journal of Alzheimer's Disease Reports 2021; 5(1): 443-468
Abstract: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study commenced in 2006 as a prospective study of 1,112 individuals (768 cognitively normal (CN), 133 with mild cognitive impairment (MCI), and 211 with Alzheimer's disease dementia (AD)) as an 'Inception cohort' who underwent detailed ssessments every 18 months. Over the past decade, an additional 1247 subjects have been added as an 'Enrichment cohort' (as of 10 April 2019). Here we provide an overview of these Inception and Enrichment cohorts of more than 8,500 person-years of investigation. Participants underwent reassessment every 18 months including comprehensive cognitive testing, neuroimaging (magnetic resonance imaging, MRI; positron emission tomography, PET), biofluid biomarkers and lifestyle evaluations. AIBL has made major contributions to the understanding of the natural history of AD, with cognitive and biological definitions of its three major stages: preclinical, prodromal and clinical. Early deployment of Aβ-amyloid and tau molecular PET imaging and the development of more sensitive and specific blood tests have facilitated the assessment of genetic and environmental factors which affect age at onset and rates of progression. This fifteen-year study provides a large database of highly characterized individuals with longitudinal cognitive, imaging and lifestyle data and biofluid collections, to aid in the development of interventions to delay onset, prevent or treat AD. Harmonization with similar large longitudinal cohort studies is underway to further these aims.
DOI: 10.3233/ADR-210005
Journal: Journal of Alzheimer's Disease Reports
PubMed URL: 34368630
Type: Journal Article
Subjects: Alzheimer’s disease
Aβ-amyloid imaging
cohort study
mild cognitive impairment
observational longitudinal
preclinical Alzheimer’s disease
prodromal Alzheimer’s disease
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jul 19, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.